Aktiesnakken — Juni 2011
-
er det en trussel - eller et løfte?
-
jamen, så ved jeg jo ikke om jeg skal være bange eller glæde mig
-
-
GEN - flere dårlige nyheder. UBS analyse: Arzerra til de to lymfekræftformer DLBCL og NHL indtil 2015/16.
-
UBS udsætter estimat for salgsindtægter og anbefaler senere køb af aktien
-
well - i det mindste er der da salgsforventninger
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind